ViewRay (VRAYQ) Competitors

In the previous week, ViewRay's average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.

T2 Biosystems has lower revenue, but higher earnings than ViewRay. T2 Biosystems is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

ViewRay has a net margin of 0.00% compared to T2 Biosystems' net margin of -563.16%.

ViewRay has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 8.16, indicating that its stock price is 716% more volatile than the S&P 500.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Comparatively, 0.0% of T2 Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

WORK Medical Technology Group has lower revenue, but higher earnings than ViewRay.

15.5% of ViewRay shares are held by institutional investors. 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Given ViewRay's higher probable upside, equities analysts plainly believe ViewRay is more favorable than WORK Medical Technology Group.

ViewRay has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, WORK Medical Technology Group has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500.

In the previous week, WORK Medical Technology Group had 2 more articles in the media than ViewRay. MarketBeat recorded 2 mentions for WORK Medical Technology Group and 0 mentions for ViewRay. WORK Medical Technology Group's average media sentiment score of 1.00 beat ViewRay's score of 0.00 indicating that WORK Medical Technology Group is being referred to more favorably in the news media.

ViewRay has a net margin of 0.00% compared to Acutus Medical's net margin of -272.74%. ViewRay's return on equity of 0.00% beat Acutus Medical's return on equity.

Acutus Medical has lower revenue, but higher earnings than ViewRay. Acutus Medical is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

15.5% of ViewRay shares are held by institutional investors. Comparatively, 56.9% of Acutus Medical shares are held by institutional investors. 2.5% of ViewRay shares are held by company insiders. Comparatively, 5.2% of Acutus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ViewRay has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Acutus Medical has a beta of 6.03, meaning that its share price is 503% more volatile than the S&P 500.

In the previous week, ViewRay's average media sentiment score of 0.00 equaled Acutus Medical'saverage media sentiment score.

In the previous week, Minerva Surgical had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for Minerva Surgical and 0 mentions for ViewRay. Minerva Surgical's average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Minerva Surgical has higher earnings, but lower revenue than ViewRay.

15.5% of ViewRay shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by insiders. Comparatively, 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Minerva Surgical has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.